Nuveen Asset Management, LLC Neu Base Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $434,807 - $689,306	-93,911 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.92 - $12.36 $146,607 - $261,858	-21,186 Reduced 18.41%	93,911 $694,000
Q4 2020 Feb 16, 2021	SELL	$6.92 - $9.25 $233,411 - $312,002	-33,730 Reduced 22.66%	115,097 $805,000
Q3 2020 Nov 16, 2020	BUY	$7.25 - $9.71 $343,577 - $460,156	47,390 Added 46.72%	148,827 $1.13 Million
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $678,613 - $1.17 Million	101,437 New	101,437 $890,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.